Chimerix, Inc. CXF.F Stock
Chimerix, Inc. Price Chart
Chimerix, Inc. CXF.F Financial and Trading Overview
| Chimerix, Inc. stock price | 0.88 EUR |
| Previous Close | 1.29 EUR |
| Open | 1.4 EUR |
| Bid | 1.32 EUR x 91600 |
| Ask | 1.39 EUR x 88100 |
| Day's Range | 1.4 - 1.4 EUR |
| 52 Week Range | 0.98 - 2.9 EUR |
| Volume | 17.11K EUR |
| Avg. Volume | 364 EUR |
| Market Cap | 126.44M EUR |
| Beta (5Y Monthly) | 1.147183 |
| PE Ratio (TTM) | 0.7777778 |
| EPS (TTM) | -0.86 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.67 EUR |
CXF.F Valuation Measures
| Enterprise Value | -102608088 EUR |
| Trailing P/E | 0.7777778 |
| Forward P/E | -5.6 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.7088008 |
| Price/Book (mrq) | 0.5160339 |
| Enterprise Value/Revenue | -3.01 |
| Enterprise Value/EBITDA | 1.831 |
Trading Information
Chimerix, Inc. Stock Price History
| Beta (5Y Monthly) | 1.147183 |
| 52-Week Change | -13.71% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.9 EUR |
| 52 Week Low | 0.98 EUR |
| 50-Day Moving Average | 1.13 EUR |
| 200-Day Moving Average | 1.62 EUR |
CXF.F Share Statistics
| Avg. Volume (3 month) | 364 EUR |
| Avg. Daily Volume (10-Days) | 30 EUR |
| Shares Outstanding | 88.58M |
| Float | 74.44M |
| Short Ratio | N/A |
| % Held by Insiders | 9.95% |
| % Held by Institutions | 64.32% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 514.96% |
| Operating Margin (ttm) | -164.62% |
| Gross Margin | -100.076% |
| EBITDA Margin | -164.34% |
Management Effectiveness
| Return on Assets (ttm) | -21.64% |
| Return on Equity (ttm) | 121.87% |
Income Statement
| Revenue (ttm) | 34.09M EUR |
| Revenue Per Share (ttm) | 0.39 EUR |
| Quarterly Revenue Growth (yoy) | 1786.70% |
| Gross Profit (ttm) | -36486000 EUR |
| EBITDA | -56029000 EUR |
| Net Income Avi to Common (ttm) | 175.56M EUR |
| Diluted EPS (ttm) | 1.8 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 214.75M EUR |
| Total Cash Per Share (mrq) | 2.42 EUR |
| Total Debt (mrq) | 2.26M EUR |
| Total Debt/Equity (mrq) | 0.94 EUR |
| Current Ratio (mrq) | 13.678 |
| Book Value Per Share (mrq) | 2.713 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -45645000 EUR |
| Levered Free Cash Flow (ttm) | -18636124 EUR |
Profile of Chimerix, Inc.
| Country | Germany |
| State | NC |
| City | Durham |
| Address | 2505 Meridian Parkway |
| ZIP | 27713 |
| Phone | 919 806 1074 |
| Website | https://www.chimerix.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 89 |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Q&A For Chimerix, Inc. Stock
What is a current CXF.F stock price?
Chimerix, Inc. CXF.F stock price today per share is 0.88 EUR.
How to purchase Chimerix, Inc. stock?
You can buy CXF.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Chimerix, Inc.?
The stock symbol or ticker of Chimerix, Inc. is CXF.F.
Which industry does the Chimerix, Inc. company belong to?
The Chimerix, Inc. industry is Biotechnology.
How many shares does Chimerix, Inc. have in circulation?
The max supply of Chimerix, Inc. shares is 89.63M.
What is Chimerix, Inc. Price to Earnings Ratio (PE Ratio)?
Chimerix, Inc. PE Ratio is now.
What was Chimerix, Inc. earnings per share over the trailing 12 months (TTM)?
Chimerix, Inc. EPS is -0.86 EUR over the trailing 12 months.
Which sector does the Chimerix, Inc. company belong to?
The Chimerix, Inc. sector is Healthcare.